Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
Bartlett, J B, Michael, A, Clarke, I A, Dredge, K, Nicholson, S, Kristeleit, H, Polychronis, A, Pandha, H, Muller, G W, Stirling, D IVolume:
90
Year:
2004
Language:
english
Pages:
7
DOI:
10.1038/sj.bjc.6601579
File:
PDF, 193 KB
english, 2004